Hexarelin

The Most Potent Growth Hormone Releasing Peptide with Unique Cardioprotective

Properties

Hexarelin is a synthetic growth hormone releasing peptide (GHRP) and one of the most potent compounds in the GHRP family. It stimulates the pituitary gland to release growth hormone by binding to ghrelin receptors. Unlike synthetic HGH injections, Hexarelin triggers the body to produce its own growth hormone rather than introducing an external hormone. The peptide is a hexapeptide, meaning it contains six amino acids. It was developed as a more potent alternative to GHRP-6 and has been shown to produce stronger growth hormone release on a dose-for-dose basis than other peptides in its class. Hexarelin is also known by the name Examorelin in the scientific literature. What makes Hexarelin unique is its cardiac effects. Research has identified that Hexarelin binds to receptors in heart tissue and may have direct cardioprotective properties independent of its growth hormone releasing effects. Studies have found Hexarelin binding sites throughout the cardiovascular system, with the highest concentrations in the heart ventricles. Hexarelin has been investigated in Phase 2 clinical trials for the treatment of congestive heart failure. Additionally, preclinical research has demonstrated that Hexarelin promotes the survival of new adult-born hippocampal cells, suggesting it may enhance adult neurogenesis. The peptide has also been shown to be orally bioavailable, unlike many other GHRPs, though subcutaneous injection remains the most common route of administration. Hexarelin is not FDA approved for any medical use. It has been studied in clinical trials but has not received approval for therapeutic applications. It remains available through peptide suppliers for research purposes.

Peptide Information

Property Value Sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 Molecular Formula C47H58N12O6 Molecular Weight 887.06 g/mol CAS Number 140703-51-1 Half-Life Approximately 30 to 70 minutes Synonyms Examorelin, Hexarelin Acetate, HEX

How Hexarelin Works (Mechanism of Action)

Hexarelin works through the ghrelin receptor pathway, similar to other growth hormone releasing peptides. However, it has additional mechanisms that set it apart from compounds like Ipamorelin.

The Primary Mechanism

When Hexarelin is injected, it binds to ghrelin receptors (GHS-R1a) located in the hypothalamus and pituitary gland. This binding triggers a cascade of intracellular signals. The receptor activates phospholipase C (PLC), which increases intracellular calcium levels. This leads to calcium-dependent release of growth hormone from somatotroph cells in the pituitary. Hexarelin also works by suppressing somatostatin, the hormone that normally inhibits growth hormone release. This dual action—stimulating release while blocking inhibition—is why Hexarelin produces such strong growth hormone pulses. Importantly, Hexarelin synergizes with coadministered GHRH and is most effective when GHRH signaling is intact.

The Growth Hormone Response

Hexarelin creates rapid, powerful spikes in growth hormone. Studies show that a single 100 mcg injection can produce growth hormone elevation comparable to injecting 10 IU of synthetic HGH. The difference is duration. With Hexarelin, levels return to baseline within 90 minutes to 2 hours. With synthetic HGH, levels stay elevated for 7 to 8 hours. This short duration means Hexarelin needs to be dosed 2 to 3 times daily for sustained effects.

Cardiac Effects

Research has identified a separate receptor for Hexarelin in heart tissue. This receptor appears to be different from the ghrelin receptor found in the pituitary. Studies using radioactively labeled Hexarelin found binding sites throughout the cardiovascular system, with the highest levels in the ventricles, followed by the atria, aorta, coronary arteries, and carotid arteries. In isolated heart studies, Hexarelin improved cardiac function and protected against damage from reduced blood flow. These effects occurred even in animals that lacked normal growth hormone signaling, suggesting the cardiac benefits are independent of growth hormone release. Research also demonstrates that Hexarelin attenuates cardiomyocyte hypertrophy and apoptosis via an autophagy-dependent mechanism associated with suppression of the mTOR signaling pathway.

Neurological Effects

Hexarelin analogue peptides have been shown to activate paraventricular oxytocinergic neurons, and the GHS-R receptor is highly expressed in multiple brain areas including the hippocampus and mesencephalic nuclei involved in dopamine and serotonin production. Preclinical studies demonstrate that Hexarelin promotes the survival of new adult-born hippocampal cells, suggesting potential neurogenic and neuroprotective properties.

Downstream Effects

The growth hormone released by Hexarelin stimulates IGF-1 production in the liver. IGF-1 is responsible for many of the anabolic effects, including muscle protein synthesis, fat metabolism, and tissue repair. Hexarelin also appears to regulate the energy dynamics of muscle cells, helping them make more efficient use of available energy.

Benefits

Most Potent Growth Hormone Release

Hexarelin produces stronger growth hormone spikes than other GHRPs, including GHRP-2, GHRP-6, and Ipamorelin. On a mcg-for-mcg basis, it is the most effective growth hormone releasing peptide available. A single 100 mcg injection can elevate growth hormone to levels comparable with much higher doses of other peptides.

Muscle Growth and Strength

Higher growth hormone and IGF-1 levels support muscle protein synthesis and cellular repair. Users report improved ability to build lean mass, increased strength, and better muscle fullness. These effects develop over weeks to months of consistent use combined with proper training.

Fat Loss

Growth hormone promotes lipolysis, the breakdown of stored fat for energy. Hexarelin users commonly report reductions in body fat, particularly around the midsection. The elevated IGF-1 also supports fat metabolism. Research suggests Hexarelin may additionally lower insulin resistance, reducing fat accumulation.

Improved Recovery

Growth hormone accelerates tissue repair at the cellular level. This translates to faster recovery between training sessions, reduced muscle soreness, and improved healing from minor injuries.

Cardiovascular Protection

Hexarelin has demonstrated cardioprotective effects in research studies. It appears to improve cardiac function, protect heart tissue from damage, and enhance coronary blood flow. These effects may be independent of its growth hormone releasing properties. Research has shown benefits in models of heart failure, reduced blood flow, and aging hearts. Hexarelin also protects cardiomyocytes from hypertrophy through autophagy-dependent mechanisms.

Better Sleep

Many users report improved sleep quality when using Hexarelin, particularly when dosed before bed. Growth hormone naturally peaks during deep sleep, and Hexarelin may enhance this process. Research confirms that GHRP administration, like GHRH, facilitates slow-wave sleep.

Bone Health

IGF-1 stimulates osteoblast activity (bone-building cells). Long-term growth hormone optimization supports bone mineral density and overall skeletal health.

Neuroprotective Potential

Preclinical research suggests Hexarelin promotes the survival of new hippocampal neurons and may have neuroprotective properties through its activity in brain regions involved in dopamine and serotonin production.

What the Science Shows

Hexarelin has been studied in both animal models and human clinical trials.

Imbimbo et al. (1994), European Journal of Clinical Pharmacology This was a double-blind, placebo-controlled, rising-dose study evaluating Hexarelin’s growth hormone releasing activity in humans:

• Hexarelin stimulated dose-dependent growth hormone release
• Subcutaneous administration was effective
• Well tolerated across tested dose ranges
• Growth hormone response was reproducible

Deghenghi et al. (1994), Life Sciences

This study examined Hexarelin’s growth hormone releasing activity in infant and adult rats:

• Hexarelin given subcutaneously produced long-lasting growth hormone release
• Slightly more effective than GHRP-6
• Described as a highly effective growth hormone releaser

Bhogal et al. (1999), Circulation Research — Cardiac Receptor Discovery This landmark study identified a new class of Hexarelin receptors in heart tissue:

• Found Hexarelin binding sites throughout the cardiovascular system
• Highest concentrations in the heart ventricles
• Hexarelin increased coronary perfusion pressure in a dose-dependent manner in isolated

rat hearts

• Effects involved L-type calcium channels and protein kinase C pathways
• Cardiac effects appeared independent of the GH/IGF-1 axis in some studies

Arvat et al. (1997), Peptides — Hormonal Effects

This study compared GHRP-2 and Hexarelin effects on GH, prolactin, ACTH, and cortisol in humans:

• Both peptides released growth hormone effectively
• Both caused some increase in ACTH and cortisol (unlike selective Ipamorelin)
• Prolactin was also affected
• These hormonal effects were dose-dependent

Desensitization Study

A study evaluating desensitization with daily use found minimal difference in growth hormone response between 1 week and 4 weeks of treatment. However, after 16 weeks of continuous use, growth hormone release was considerably blunted. Importantly, 4 weeks after discontinuation, desensitization was completely reversed.

Berlanga-Acosta et al. (2017), SAGE Open Medicine — Cytoprotective

Review

This comprehensive review examined the historical evidence supporting the cytoprotective effects of synthetic GHRPs including Hexarelin. It documented cardioprotective, neuroprotective, and tissue-protective properties across multiple preclinical models, including effects on mitochondrial integrity and muscle calcium homeostasis under chemotherapy- associated stress conditions.

Dosing Protocol

Hexarelin is typically dosed 2 to 3 times daily via subcutaneous injection. Due to its potency and faster desensitization compared to other GHRPs, cycling is essential.

Standard Protocol

Parameter Standard Beginner Advanced Dose per injection 100–200 mcg 100 mcg 200 mcg Frequency 2–3x daily 2x daily 3x daily Cycle length 4–8 weeks 4 weeks 8–12 weeks max Off period 4 weeks minimum 4–6 weeks 4 weeks minimum

Beginner Protocol

• Weeks 1 to 2: 100 mcg twice daily (morning and before bed)
• Weeks 3 to 4: 200 mcg twice daily
• Weeks 5 to 8: 200 mcg three times daily (optional)
• After cycle: 4 to 6 weeks off

Important Considerations

• Hexarelin desensitizes receptors faster than other GHRPs like Ipamorelin. Research

shows that after 16 weeks of continuous use, growth hormone response is significantly blunted. Cycling is essential.

• Take on an empty stomach, at least 1 hour before eating or 3 hours after eating. Food,

especially carbohydrates, raises insulin and blunts the growth hormone response.

• Unlike Ipamorelin, Hexarelin does cause some increase in cortisol and prolactin. This is

generally mild at therapeutic doses but is worth monitoring, especially with longer use.

Draw Volumes by Vial Size

5 mg Vial (2 mL reconstitution = 2.5 mg/mL) — Recommended

Dose Volume Syringe Units Vial Duration (2x/day) 100 mcg 0.04 mL 4 units ~25 days 150 mcg 0.06 mL 6 units ~17 days 200 mcg 0.08 mL 8 units ~12 days 250 mcg 0.10 mL 10 units ~10 days 300 mcg 0.12 mL 12 units ~8 days

5 mg Vial (1 mL reconstitution = 5 mg/mL)

Dose Volume Syringe Units 100 mcg 0.02 mL 2 units 150 mcg 0.03 mL 3 units 200 mcg 0.04 mL 4 units 250 mcg 0.05 mL 5 units 300 mcg 0.06 mL 6 units

Very small volumes at the 5 mg/mL concentration. The 2 mL reconstitution is recommended for easier measurement.

Reconstitution Instructions

1. Wipe the vial stopper and bacteriostatic water vial with alcohol swabs. 2. Draw 1 to 2 mL of bacteriostatic water into a sterile syringe. 3. Insert the needle through the rubber stopper at an angle.

4. Let the water trickle slowly down the inside wall of the vial. Do not inject directly onto the powder. 5. Swirl gently until fully dissolved. Do not shake. 6. The solution should be clear. If cloudy or if it contains particles, do not use. 7. Label the vial with the date and concentration.

Side Effects

Common Effects

• Injection site redness or irritation
• Water retention
• Tingling or numbness in hands (transient)
• Increased appetite
• Head rush or flushing after injection
• Lethargy (especially initially)

Hormonal Effects

• Mild cortisol increase (can cause anxiety, irritability, or sleep issues at higher doses)
• Mild prolactin increase (can affect libido in some individuals)
• These effects are dose-dependent and generally manageable

Desensitization

Hexarelin desensitizes receptors faster than other GHRPs. After extended continuous use (16 or more weeks), growth hormone response becomes blunted. This reverses completely with 4 or more weeks off.

Rare Effects

• Joint stiffness (from elevated GH)
• Carpal tunnel symptoms (usually at very high doses)

Contraindications and Precautions

Do Not Use

• Active cancer or history of cancer
• Diabetic retinopathy
• Pregnancy or breastfeeding

Use with Caution

• Diabetes or pre-diabetes (monitor blood sugar)
• Cardiovascular disease (though research suggests benefits, consult a physician)
• History of carpal tunnel syndrome
• Anxiety disorders (due to potential cortisol effects)

Drug Interactions

Growth hormone can affect insulin sensitivity. If using insulin or diabetes medications, blood sugar management may change. Glucocorticoids may blunt the growth hormone response.

Comparison to Other Growth Hormone Releasing Peptides

Compound GH Potency Selectivity Cortisol Appetite Cycling Effect Needed Hexarelin Highest Low Mild increase Moderate Yes (essential) GHRP-2 High Moderate Mild increase Moderate Recommended GHRP-6 Moderate Low Mild increase Strong Recommended Ipamorelin Moderate Highest None Minimal Less critical MK-677 Moderate Low Mild increase Strong Recommended

Hexarelin is the most potent but has more side effects and faster desensitization. Ipamorelin is the most selective with the fewest side effects. The choice depends on priorities: maximum GH output (Hexarelin) versus cleanest side effect profile (Ipamorelin). Hexarelin’s unique cardiac benefits may also factor into the decision for some users.

Success Tips

Cycle Properly

The most important consideration with Hexarelin is cycling. Do not run it continuously for more than 8 to 12 weeks. Take at least 4 weeks off between cycles to allow receptor sensitivity to recover. Research shows complete reversal of desensitization occurs within 4 weeks of discontinuation.

Stack with GHRH for Maximum Effect

Hexarelin can be combined with a GHRH peptide like CJC-1295 without DAC (Mod GRF 1-29) for enhanced growth hormone release. The GHRH amplifies the signal while Hexarelin provides the potent pulse. This combination produces more growth hormone than either compound alone.

Time It Right

Take on an empty stomach. Wait at least 1 hour after injection before eating. The best times are first thing in the morning (fasted) and before bed.

Start Lower

Begin with 100 mcg twice daily to assess tolerance before increasing. Hexarelin is very potent, and most users do not need maximum doses to see results.

Monitor Your Response

Pay attention to how you feel. If increased anxiety, sleep issues, or other cortisol-related symptoms appear, consider reducing the dose or taking a break.

Support with Training and Nutrition

Hexarelin provides the hormonal environment for growth, but training stimulus and proper nutrition are still essential. Resistance training 3 to 4 times per week and adequate protein (0.8 to 1.0 grams per pound of body weight) are required to maximize results.

Storage and Handling

Before Reconstitution

• Store lyophilized (powder) vials in the freezer at −20°C (−4°F)
• Can also be stored in the refrigerator at 2°C to 8°C (36°F to 46°F)
• Protect from light
• Do not use past the expiration date

After Reconstitution

• Refrigerate at 2°C to 8°C (36°F to 46°F)
• Use within 14 to 28 days
• Do not freeze after reconstitution
• Keep the stopper clean between uses
• If the solution becomes cloudy or contains particles, discard and use a new vial

Legal Status

United States: Hexarelin is not FDA approved for any medical use. It is classified as a research chemical and is available through peptide suppliers for research purposes. WADA Status: Hexarelin is prohibited at all times as a growth hormone secretagogue under World Anti-Doping Agency rules. Competitive Athletes: Do not use if subject to drug testing.

Frequently Asked Questions

Is Hexarelin stronger than Ipamorelin?

Yes, Hexarelin produces stronger growth hormone release than Ipamorelin. However, Ipamorelin is more selective and does not affect cortisol or prolactin. The tradeoff is potency versus side effect profile. Why does Hexarelin require cycling? Hexarelin desensitizes ghrelin receptors faster than other GHRPs. Research shows that after 16 weeks of continuous use, growth hormone response is significantly reduced. Taking 4 or more weeks off allows receptors to recover their sensitivity.

Can I use Hexarelin with CJC-1295?

Yes. Combining Hexarelin with CJC-1295 without DAC (Mod GRF 1-29) produces enhanced growth hormone release. The CJC-1295 extends the pulse while Hexarelin provides potency. This is a common stack for maximizing growth hormone output. How long until I see results? Sleep improvements and increased recovery often appear within 1 to 2 weeks. Body composition changes typically become noticeable at 6 to 8 weeks. Full effects develop over months. Will Hexarelin increase my appetite? Hexarelin can increase appetite because it activates ghrelin receptors. The effect is less intense than GHRP-6 but more noticeable than Ipamorelin. Does Hexarelin suppress natural growth hormone? Hexarelin stimulates the pituitary to produce its own growth hormone. It does not replace the hormone. With proper cycling, pituitary function remains intact. Desensitization from extended use reverses with time off. Is Hexarelin orally bioavailable? Research indicates Hexarelin is orally bioavailable, unlike many other GHRPs. However, subcutaneous injection remains the standard and most effective route of administration for research purposes.

References

1. Imbimbo BP, et al. Growth hormone-releasing activity of hexarelin in humans. European Journal of Clinical Pharmacology. 1994;46(5):421-425. 2. Deghenghi R, et al. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences. 1994;54(18):1321-1328. 3. Bhogal R, et al. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circulation Research. 1999;84(8):1-7.

4. Arvat E, et al. Effects of GHRP-2 and hexarelin, alone and combined with GHRH, on GH, prolactin, ACTH and cortisol levels in man. Peptides. 1997;18(6):885-891. 5. Ghigo E, et al. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460. 6. Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. SAGE Open Medicine. 2017;5:1-22.